Follow-on investment in hemotune
Successful closing of the CHF 14 million Series B2 of hemotune under the lead of Belmondo and with the participation of OCCIDENT, as well as existing and new investors.
News
Resistell is publishing in Nature!
A peer-reviewed article on Resistell's rapid phenotypic solution for antibiotic susceptibility testing (AST) has been published in Nature Communications.
Follow-on investment in Tubulis
OCCIDENT is excited to announce its participation in Tubulis' €128 million Series B2 round co-led by EQT Life Sciences and Nextech Invest.
Initial Investment in Altavo
OCCIDENT is taking the lead in the oversubscribed €5 million Series A round of this Dresden-based MedTech start-up.
Avelo receives a 1.5M Innosuisse Grant
Following the Eurostars grant in October, our portfolio company Avelo, a Swiss breath diagnostics start-up, has been awarded the next grant.
Tubulis out-licenses TUB-010
Tubulis has inked its second major deal this year! As part of the deal, Tubulis out-licenses the Antibody-Drug Conjugate TEQ102 to Oncoteq.
Avelo wins €1.5 million Eurostars Grant
Avelo is now part of a consortium of three companies, including VIVOLTA from the Netherlands and BLINK from Germany.
Successful Exit adivo
We are excited to announce the successful exit of our portfolio company adivo, which we have supported from the very beginning as one of the first investors.
Initial Investment in EBAMed
OCCIDENT invests in the Geneva-based company specializing in the development of novel image guidance systems for ventricular arrhythmias using proton therapy.